Disclosure of material transactions with related parties in accordance with Section 111c(1) Sentence 1 of the German Stock Corporation Act (AktG)

Planegg-Martinsried, Germany, October 20, 2026 – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) (“Company”) today entered into cooperation agreements with each Biocelys S.A., based in Canelones, Uruguay, and Santo Biosimilar GmbH, based in Munich, in connection with a biosimilar candidate. ATHOS KG indirectly holds more than 20% of the Company’s shares and voting rights through Santo Holding (Deutschland) GmbH. ATHOS KG indirectly controls both Santo Biosimilar GmbH and Biocelys S.A. Biocelys S.A. and Santo Biosimilar GmbH are therefore related parties of the Company within the meaning of Section 111a AktG.

The cooperation agreement with Biocelys S.A. covers the joint development, as well as the manufacture, regulatory approval, and supply management of the biosimilar candidate. In this context, the Company will grant Santo Biosimilar GmbH a permanent, irrevocable, and sublicensable license to a clone cell and will provide certain development services to carry out the project. The cooperation agreement with Santo Biosimilar GmbH covers the financing of the project by Santo Biosimilar GmbH in exchange for the exclusive assignment of ownership rights to the results of the work to Santo Biosimilar GmbH.

The management board expects that, in connection with the cooperation with Biocelys S.A. and Santo Biosimilar GmbH, the Company will transfer and/or provide rights and services (including interest) with a fair value of EUR 40 – 45 million. For the development and support services to be provided by the Company as part of the project, the Company will receive compensation on an hourly basis with a margin in the low double-digit percentage range, as well as service fees. In addition, the Company will participate in future revenues of Santo Biosimilar GmbH in the low double-digit percentage share, from which the project costs, including interest, will be deducted first. Payment of the Company’s share of the proceeds is expected to begin in 2036.

The Company’s supervisory board approved the aforementioned transactions on July 23, 2026, in accordance with Section 111b(1) AktG.